Novartis eyes oral MS drug as potential blockbuster.
Mark
M
Ratner
D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000191:economics; D004345:Drug Industry / Q000191:economics; D000068876:Fingolimod Hydrochloride; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008246:Lysophospholipids / Q000378:metabolism; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D011409:Propylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000378:metabolism / Q000627:therapeutic use
D008246:Lysophospholipids; D011409:Propylene Glycols; C060506:sphingosine 1-phosphate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine